|Headquarters||Dhanmondi, Dhaka, Bangladesh|
|Key people||Nazmul Hassan CEO|
Beximco Pharma started operations in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of USA. It has now grown to become a leading pharmaceutical company in Bangladesh, and it supplies more than 10% of country's total medicinal needs. Today Beximco Pharma manufactures and markets its own branded generics for several diseases including AIDS, cancer, asthma, hypertension, and diabetes for both national and international markets. 1976 : Registration of the company 1980 : Started manufacturing and marketing of licensee products of Bayer AG of Germany and Upjohn Inc. of USA 1983 : Launching of Beximco Pharma’s own brands 1985 : Listing in the Dhaka Stock Exchange (DSE) 1990 : Commissioning of Basic Chemical (APIs) unit 1992 : Started export operation with Active Pharmaceutical Ingredients (APIs) 1993 : First export market operation with finished formulations 1996 : Introduction of Sustained Release Dosage form 1997 : Introduction of Suppository Dosage form; Commissioning of Metered Dose Inhaler (MDI) plant; Introduction of Metered Dose Nasal Spray 1998 : First pharmaceutical company of the country achieving 'National Export Trophy (Gold)' for 1994-95 1999 : UNICEF approval of Beximco Pharma as an enlisted supplier 2000 : Agreement to manufacture Metered Dose Inhaler (MDI) for GlaxoSmithKline 2001 : Introduction of Small Volume Parenteral (SVP) products; establishment of Analgesic-Antiinflammatory bulk drug plant 2002 : Won the first prize of ICAB National Awards 2000 for 'Best Published Accounts and Reports' in Non-Financial Sector Category The first Bangladeshi company to supply pharmaceuticals to Raffles Hospital- the most prestigious hospital in Singapore 2003 : Received “National Export Trophy (Gold)” for consecutive 2 years (1998-99, 1999-2000) Won the Silver prize of ICAB National Awards 2003 for 'Best Published Accounts and Reports' in Non-Financial Sector Category Won a tender to supply Neoceptin R and Neofloxin to Raffles Hospital of Singapore for whole year's consumption Introduced Anti-HIV drugs for the first time in Bangladesh Diversification into Anti-Cancer therapeutic class 2004 : Signed contract with Novartis to manufacture their liquid, cream, ointment and suppository products under “Toll Manufacturing” agreement 2005 : Merger of Beximco Infusions Ltd. with Beximco Pharmaceuticals Ltd. Admission to Alternative Investment Market (AIM) of London Stock Exchange (LSE) 2006 : New USFDA standard Oral Solid Dosage (OSD) Plant Commissioned Successfully relocated/outsourced penicillin and cephalosporin manufacturing facilities as per cGMP guidelines Introduced generic oseltamivir in Bangladesh Launched CFC free ozone benign HFA inhalers as the first company in BangladeshStatus: Public Limited Company
Business Lines: Manufacturing and marketing of pharmaceutical Finished Formulation Products, Large Volume Parenterals and Active Pharmaceutical Ingredients (APIs) Overseas Offices & Associates: Australia, Bhutan, Cambodia, Chile, Ghana, Hong Kong, Indonesia, Jordan, Kenya, Malaysia, Myanmar, Nepal, Pakistan, Philippines, Singapore, Sri Lanka, Vietnam and Yemen
Authorized Capital (Taka): 2,000 million
Paid-up Capital (Taka): 1,145.07 million
Number of Shareholders: Around 54,000
Stock Exchange Listings: Dhaka, Chittagong and AIM of London Stock Exchanges
Number of Employees: 2,384
Beximco Pharma manufacturing facilities are spread across a 20-acre (81,000 m2) site located in Dhaka, Bangladesh. The facilities comprise of a number of purpose-built plants, including a new Oral Solid Dosage (OSD) plant. The site includes manufacturing facilities as well as a research laboratory and a number of warehouses. The plant and machinery of the facilities were designed, produced and installed by partners from Germany, Switzerland, Sweden, Italy and the United Kingdom, amongst others.
On August, 2007, Beximco exported its medicines to the Philippines, the 5th country of the 10-member Association of South East Asian Nations (ASEAN) to import Beximco's drugs. Beximco Chief Executive Nazmul Hassan said that exports to the Philippines include metered dose inhalers, and nasal sprays, and other medications. The Philippine pharmaceutical market ($1.3 billion in 2007), is highly dependent on imported medicines.